CDI Laboratories Inc.

CDI Laboratories Inc., a self-certified small disadvantaged business and manufacturer based in Mayagüez, Puerto Rico, provides protein microarray assays and biospecimen screening services to federal research institutions as a prime contractor (100% of recent awards) with no subcontract footprint. The company operates on firm-fixed-price purchase orders across biomedical and immunological research platforms, with all work performed at its Puerto Rico facilities.

CDI Laboratories' product portfolio centers on human proteome microarray platforms and viral antibody profiling services. Its flagship HuProt v4.0 array contains over twenty-one thousand human proteins from more than sixteen thousand genes with reproducibility exceeding ninety-five percent; the company also offers VirScan viral antibody profiling, VirD G-protein coupled receptor screening, and PHIP-Seq HuScan sequencing assays. Representative work includes a $121 thousand purchase order from the National Heart, Lung, and Blood Institute in September 2023 for HuProt v4.0 array services under a total small business set-aside, a $200 thousand National Institute on Drug Abuse purchase order in June 2023 for HuProt v4.0 and VirD protein arrays supporting autoantibody research, and a $49.4 thousand National Cancer Institute purchase order in July 2026 for NCI PhIP-Seq HuScan service with performance due July 2027. Most recent awards carry no set-aside designation and employ simplified acquisition procedures.

Customer concentration is heavily NIH-weighted. The Department of Health and Human Services National Institutes of Health accounts for the vast majority of awards across five constituent institutes. The National Institute on Aging leads by both count and dollars (fourteen awards, $427 thousand combined potential value), followed by the National Institute of Allergy and Infectious Diseases (eight awards, $256 thousand), the National Institute on Drug Abuse (two awards, $223 thousand), and the National Heart, Lung, and Blood Institute (two awards, $146 thousand). The Veterans Health Administration's Veterans Integrated Service Network 4 placed one award valued at $98 thousand. These five customers account for 78% of award count and 85% of combined potential value. The vendor has served thirteen distinct federal agencies since 2010.

Activity has declined materially. CDI received four awards in 2022, three in 2023, and only one award in each of 2024, 2025, and 2026. Combined potential value across the forty-one awards in source data totals $1.4 million, though obligated dollars across all awards reach $2.2 million (163% of potential value), suggesting significant invoicing against prior-year purchase orders. Only one award ($49 thousand) reaches ultimate completion within the next twenty-four months, indicating minimal recompete pressure in that window. The company does not hold seats on government-wide acquisition contracts or blanket purchase agreements; all work flows through direct agency purchase orders issued under simplified acquisition procedures. Category concentration in the award history clusters across reference laboratory testing (nineteen awards), testing laboratories and services (thirteen awards), and research and development in biotechnology (seven awards).